With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.
To a solution of acetic acid 2-acetoxy-2-[3-(allyl-methyl-carbamoyl)-5- chlorocarbonyl^Atheta-triiodo-phenylcarbamoyll-ethyl ester (17) (3.7g, 5.10mmol) in dichloromethane (2OmL) was added 1 ,4,7-triazacyclononane (200mg, 1.55mmol) followed by triethylamine (650mul_, 5.10mmol). The reaction mixture was stirred at 5O0C for 48h. After cooling to ambient temperature, ethyl acetate (5OmL) was added, and the white precipitate collected. Purification by column chromatography, eluting with ethyl acetate:methanol(10 – 50%, 12 column volumes, SiO2, 25Og) gave the desired product as an off white solid (2g, 53%). LCMS was carried out Luna C18 250 LCMS shown one major peak with a mass of 1215.83 (M/2 + H+) and a purity of 85%.
4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Patent; GE HEALTHCARE AS; WO2008/123779; (2008); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI